• 

  Tumor cells directly from patients, closer to the characteristics of actual lesions.

• 

  CTCs naturally carry invasive and metastatic capabilities and are an ideal source for identifying high-risk targets.

• 

  Identify new targets related to cancer progression and drug resistance through multi-omics analysis.

• 

  Excavate the characteristics of different subgroups and identify targets with greater therapeutic value.

• 

  Early rapid validation of targets to improve R&D efficiency and success rate.

Test Duration: 2-3 Days

• 

  Informed Consent Form

• 

   

• 

  Collect 5-10 ml of Blood
  or Pleural Effusion, Ascites, Cerebrospinal Fluid

• 

   

• 

  Enrichment and Purification

• 

   

• 

  Pathological Analysis Report

Meets any of the following criteria (applicable to any solid tumor):
-People with solid tumors who need targeted drugs
-People with solid tumors who are using targeted drugs